Transgenomic Sales Slip 6 Percent; Firm Sees Strong Finish for Year

The firm trimmed its losses and selling costs, and it expects to launch a K-Ras test shortly.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.